Revenue: As of FY2026 Q1, the actual value is USD 9.893 M.EPS: As of FY2026 Q1, the actual value is USD 0.62.EBIT: As of FY2026 Q1, the actual value is USD -13 M.<h4>Segment Revenue</h4>奥麦罗制药 (Omeros Corporation) launched YARTEMLEA® in the U.S. market in January 2026. During the first quarter of 2026, gross product sales were $11.1 million, and associated net sales were $9.9 million after deductions. <h4>Operational Metrics</h4><ul><li>Net Income (Loss): For the first quarter of 2026, net income was $56.1 million, or $0.78 per share, significantly improving from a net loss of - $33.5 million, or - $0.58 per share, for the first quarter of 2025. </li><li>Non-GAAP Adjusted Net Loss: Excluding a $73.1 million non-cash gain, the non-GAAP adjusted net loss for the three months ended March 31, 2026, was - $17.1 million, or - $0.24 per share. </li><li>Loss from Operations: Loss from operations for the first quarter of 2026 was - $17.421 million, compared to - $34.969 million for the first quarter of 2025. </li><li>Total Operating Expenses: Total operating expenses for the three months ended March 31, 2026, were $27.3 million, a decrease of $7.7 million from $35.0 million for the same period in 2025, primarily due to reduced OMS906-related research and development work. </li><li>Interest Expense: Interest expense increased by $2.2 million to $5.894 million for the three months ended March 31, 2026, from $3.654 million in the prior year period, mainly due to interest on the 2029 Notes. </li><li>Interest and Other Income: Interest and other income was $1.5 million for the first quarter of 2026, up from $1.1 million for the first quarter of 2025, attributed to higher cash and investment balances. </li><li>Net Income from Discontinued Operations: Net income from discontinued operations, net of tax, was $4.8 million, or $0.07 per share, for the three months ended March 31, 2026, compared to $4.1 million, or $0.07 per share, in the prior year period. </li></ul><h4>Cash and Investments</h4>As of March 31, 2026, 奥麦罗制药 (Omeros Corporation) had $135.3 million in cash and short-term investments. <h4>Debt</h4>In February 2026, the remaining $17.1 million aggregate principal amount of the 2026 unsecured convertible notes was repaid at maturity. The only remaining debt outstanding is $70.8 million aggregate principal amount of the 2029 Notes, maturing in June 2029. <h4>Share Repurchase</h4>During the first quarter of 2026, 奥麦罗制药 (Omeros Corporation) repurchased and retired approximately 0.4 million shares of common stock at an average cost of $11.70 per share, for an aggregate purchase price of $4.2 million. <h4>Outlook / Guidance</h4>A marketing authorization application for YARTEMLEA is currently under review by the European Medicines Agency, with a decision expected in mid-2026. The U.S. Centers for Medicare &amp; Medicaid Services assigned a permanent J-code specific for YARTEMLEA, effective July 1, 2026, and recommended approval of the New Technology Add-On Payment for YARTEMLEA, expected to be effective October 1, 2026. 奥麦罗制药 (Omeros Corporation) is also targeting the initiation of an in-patient clinical trial for OMS527 for cocaine use disorder by year-end 2026.

Omeros | 8-K: FY2026 Q1 Revenue: USD 9.893 M